GSA Capital Partners LLP Acquires Shares of 413,545 ALX Oncology Holdings Inc. $ALXO

GSA Capital Partners LLP acquired a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 413,545 shares of the company’s stock, valued at approximately $856,000. GSA Capital Partners LLP owned approximately 0.31% of ALX Oncology as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. venBio Partners LLC lifted its holdings in shares of ALX Oncology by 32.8% in the 1st quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock valued at $25,834,000 after acquiring an additional 3,184,713 shares during the last quarter. Redmile Group LLC increased its stake in ALX Oncology by 143.9% during the first quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after acquiring an additional 4,699,470 shares during the last quarter. Vivo Capital LLC bought a new stake in ALX Oncology during the first quarter worth approximately $6,385,000. Orbimed Advisors LLC purchased a new stake in ALX Oncology during the first quarter valued at approximately $5,747,000. Finally, Acadian Asset Management LLC raised its position in ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after purchasing an additional 186,883 shares during the period. 97.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on ALXO. Weiss Ratings cut ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $4.60.

ALX Oncology Stock Performance

ALX Oncology stock opened at $2.08 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. The company has a market capitalization of $287.62 million, a PE ratio of -1.84 and a beta of 0.42. The company has a 50 day moving average price of $1.93 and a 200-day moving average price of $1.96. ALX Oncology Holdings Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $2.66.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. As a group, equities analysts forecast that ALX Oncology Holdings Inc. will post -0.61 earnings per share for the current year.

ALX Oncology Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.